Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR (original) (raw)

• Glass, C. K. & Rosenfeld, M. G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14, 121–141 (2000).
  Article CAS PubMed Google Scholar
• Keller, H. et al. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl Acad. Sci. USA 90, 2160–2164 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R. & Mangelsdorf, D. J. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature 383, 728–731 (1996). This study identified oxysterols as endogenous ligands for LXR.
  Article CAS PubMed Google Scholar
• Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365–1368 (1999). The first demonstration that bile acids are endogenous ligands for FXR.
  Article CAS PubMed Google Scholar
• Zelcer, N. & Tontonoz, P. Liver X receptors as integrators of metabolic and inflammatory signalling. J. Clin. Invest. 116, 607–614 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Hong, C. & Tontonoz, P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 18, 461–467 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Apfel, R. et al. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell. Biol. 14, 7025–7035 (1994).
  CAS PubMed PubMed Central Google Scholar
• Willy, P. J. et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9, 1033–1045 (1995).
  Article CAS PubMed Google Scholar
• Repa, J. J. & Mangelsdorf, D. J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16, 459–481 (2000).
  Article CAS PubMed Google Scholar
• Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J. & Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature Med. 9, 213–219 (2003).
  Article CAS PubMed Google Scholar
• Rust, S. et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genet. 22, 352–355 (1999).
  Article CAS PubMed Google Scholar
• Bodzioch, M. et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet. 22, 347–351 (1999).
  Article CAS PubMed Google Scholar
• Brooks-Wilson, A. et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet. 22, 336–345 (1999).
  Article CAS PubMed Google Scholar
• Venkateswaran, A. et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα. Proc. Natl Acad. Sci. USA 97, 12097–12102 (2000). This work identified ACBA1 as a target gene for LXR and established the requirement for ABCA1 in LXR-dependent cholesterol efflux.
  Article CAS PubMed PubMed Central Google Scholar
• Repa, J. J. et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524–1529 (2000). This study shows that LXR regulates ABCA1 expression and cholesterol absorption.
  Article CAS PubMed Google Scholar
• Kennedy, M. A. et al. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 276, 39438–39447 (2001).
  Article CAS PubMed Google Scholar
• Tarling, E. J. & Edwards, P. A. ATP binding cassette transporter G1 (ABCG1) is an intracellular sterol transporter. Proc. Natl Acad. Sci. USA 108, 19719–19724 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, N., Lan, D., Chen, W., Matsuura, F. & Tall, A. R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl Acad. Sci. USA 101, 9774–9779 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Kennedy, M. A. et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 1, 121–131 (2005). This paper outlined the importance of ABCG1 in whole-body sterol metabolism.
  Article CAS PubMed Google Scholar
• Hong, C. et al. Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target. J. Lipid Res. 52, 531–539 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Mak, P. A. et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors-α and -β. J. Biol. Chem. 277, 31900–31908 (2002).
  Article CAS PubMed Google Scholar
• Laffitte, B. A. et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl Acad. Sci. USA 98, 507–512 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Ken-Dror, G., Talmud, P. J., Humphries, S. E. & Drenos, F. APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men. Mol. Med. 16, 389–399 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Plump, A. S. et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343–353 (1992).
  Article CAS PubMed Google Scholar
• Laffitte, B. A. et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell. Biol. 23, 2182–2191 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Luo, Y. & Tall, A. R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 105, 513–520 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, Y., Repa, J. J., Gauthier, K. & Mangelsdorf, D. J. Regulation of lipoprotein lipase by the oxysterol receptors, LXRα and LXRβ. J. Biol. Chem. 276, 43018–43024 (2001).
  Article CAS PubMed Google Scholar
• Peet, D. J. et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell 93, 693–704 (1998). The first study to describe the Lxra -knockout mouse and to identify CYP7A1 as an LXR target.
  Article CAS PubMed Google Scholar
• Repa, J. J. et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. Genes Dev. 14, 2819–2830 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Schultz, J. R. et al. Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831–2838 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Repa, J. J. et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors-α and -β. J. Biol. Chem. 277, 18793–18800 (2002).
  Article CAS PubMed Google Scholar
• Berge, K. E. et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290, 1771–1775 (2000).
  Article CAS PubMed Google Scholar
• Yasuda, T. et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler. Thromb. Vasc. Biol. 30, 781–786 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• van der Velde, A. E. et al. Direct intestinal cholesterol secretion contributes significantly to total faecal neutral sterol excretion in mice. Gastroenterology 133, 967–975 (2007).
  Article CAS PubMed Google Scholar
• van der Veen, J. N. et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J. Biol. Chem. 284, 19211–19219 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Duval, C. et al. Niemann–Pick C1 like 1 gene expression is downregulated by LXR activators in the intestine. Biochem. Biophys. Res. Commun. 340, 1259–1263 (2006).
  Article CAS PubMed Google Scholar
• Zelcer, N., Hong, C., Boyadjian, R. & Tontonoz, P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325, 100–104 (2009). This study identifies IDOL as a novel LXR target, establishing a direct link between LXR and LDL uptake.
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, L. et al. The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor. Genes Dev. 25, 1262–1274 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Calkin, A. C. et al. FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors. Proc. Natl Acad. Sci. USA 108, 20107–20112 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Hong, C. et al. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J. Biol. Chem. 285, 19720–19726 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tobin, K. A. et al. Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis. J. Biol. Chem. 277, 10691–10697 (2002).
  Article CAS PubMed Google Scholar
• Chen, G., Liang, G., Ou, J., Goldstein, J. L. & Brown, M. S. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc. Natl Acad. Sci. USA 101, 11245–11250 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Mitro, N. et al. The nuclear receptor LXR is a glucose sensor. Nature 445, 219–223 (2007).
  Article CAS PubMed Google Scholar
• Kalaany, N. Y. et al. LXRs regulate the balance between fat storage and oxidation. Cell Metab. 1, 231–244 (2005).
  Article CAS PubMed Google Scholar
• Hummasti, S. et al. Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target. J. Lipid Res. 45, 616–625 (2004).
  Article CAS PubMed Google Scholar
• Gerin, I. et al. LXRβ is required for adipocyte growth, glucose homeostasis, and β-cell function. J. Biol. Chem. 280, 23024–23031 (2005).
  Article CAS PubMed Google Scholar
• Stulnig, T. M. et al. Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol. Pharmacol. 62, 1299–1305 (2002).
  Article CAS PubMed Google Scholar
• Fernandez-Veledo, S., Nieto-Vazquez, I., Rondinone, C. M. & Lorenzo, M. Liver X receptor agonists ameliorate TNFα-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression. Diabetologia 49, 3038–3048 (2006).
  Article CAS PubMed Google Scholar
• Dalen, K. T., Ulven, S. M., Bamberg, K., Gustafsson, J. A. & Nebb, H. I. Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor-α. J. Biol. Chem. 278, 48283–48291 (2003).
  Article CAS PubMed Google Scholar
• Ross, S. E. et al. Microarray analyses during adipogenesis: understanding the effects of Wnt signalling on adipogenesis and the roles of liver X receptor-α in adipocyte metabolism. Mol. Cell. Biol. 22, 5989–5999 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Korach-Andre, M., Archer, A., Barros, R. P., Parini, P. & Gustafsson, J. A. Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity. Proc. Natl Acad. Sci. USA 108, 403–408 (2011).
  Article CAS PubMed Google Scholar
• Laffitte, B. A. et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl Acad. Sci. USA 100, 5419–5424 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Stenson, B. M. et al. Activation of liver X receptor regulates substrate oxidation in white adipocytes. Endocrinology 150, 4104–4113 (2009).
  Article CAS PubMed Google Scholar
• Korach-Andre, M. et al. Liver X receptors regulate de novo lipogenesis in a tissue-specific manner in C57BL/6 female mice. Am. J. Physiol. Endocrinol. Metab. 301, E210–E222 (2011).
  Article CAS PubMed Google Scholar
• Ogihara, T. et al. Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling. J. Biol. Chem. 285, 5392–5404 (2010).
  Article CAS PubMed Google Scholar
• Efanov, A. M., Sewing, S., Bokvist, K. & Gromada, J. Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic β-cells. Diabetes 53 (Suppl. 3), 75–78 (2004).
  Article Google Scholar
• Forman, B. M. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687–693 (1995).
  Article CAS PubMed Google Scholar
• Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362–1365 (1999). This study shows that bile acids are endogenous ligands for FXR.
  Article CAS PubMed Google Scholar
• Song, C. S. et al. Dehydroepiandrosterone sulphotransferase gene induction by bile acid activated farnesoid X receptor. J. Biol. Chem. 276, 42549–42556 (2001).
  Article CAS PubMed Google Scholar
• Pircher, P. C. et al. Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 278, 27703–27711 (2003).
  Article CAS PubMed Google Scholar
• Goodwin, B. et al. A regulatory cascade of the nuclear receptors, FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517–526 (2000). This study demonstrates that FXR negatively regulates genes such as CYP7A1 via induction of SHP.
  Article CAS PubMed Google Scholar
• Lu, T. T. et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6, 507–515 (2000).
  Article CAS PubMed Google Scholar
• Huber, R. M. et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 290, 35–43 (2002).
  Article CAS PubMed Google Scholar
• Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731–744 (2000). The first study characterizing the Fxr -knockout mouse, describing effects on bile acids, cholesterol and triglycerides.
  Article CAS PubMed Google Scholar
• Zhang, M. & Chiang, J. Y. Transcriptional regulation of the human sterol 12α-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4α in mediating bile acid repression. J. Biol. Chem. 276, 41690–41699 (2001).
  Article CAS PubMed Google Scholar
• Holt, J. A. et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581–1591 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217–225 (2005).
  Article CAS PubMed Google Scholar
• Strautnieks, S. S. et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nature Genet. 20, 233–238 (1998).
  Article CAS PubMed Google Scholar
• de Vree, J. M. et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl Acad. Sci. USA 95, 282–287 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Moschetta, A., Bookout, A. L. & Mangelsdorf, D. J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nature Med. 10, 1352–1358 (2004). This study demonstrates that treatment with an FXR agonist reduces disease in a model that recapitulates human cholesterol gallstone disease.
  Article CAS PubMed Google Scholar
• Chen, F. et al. Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem. 278, 19909–19916 (2003).
  Article CAS PubMed Google Scholar
• Grober, J. et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-_cis_-retinoic acid receptor heterodimer. J. Biol. Chem. 274, 29749–29754 (1999).
  Article CAS PubMed Google Scholar
• Landrier, J. F., Eloranta, J. J., Vavricka, S. R. & Kullak-Ublick, G. A. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and -β genes. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G476–G485 (2006).
  Article CAS PubMed Google Scholar
• Gnerre, C., Blattler, S., Kaufmann, M. R., Looser, R. & Meyer, U. A. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14, 635–645 (2004).
  Article CAS PubMed Google Scholar
• Lee, F. Y. et al. Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity. Mol. Endocrinol. 24, 1626–1636 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lambert, G. et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278, 2563–2570 (2003).
  Article CAS PubMed Google Scholar
• Kast, H. R. et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 15, 1720–1728 (2001).
  Article CAS PubMed Google Scholar
• Claudel, T. et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125, 544–555 (2003).
  Article CAS PubMed Google Scholar
• Sirvent, A. et al. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett. 566, 173–177 (2004).
  Article CAS PubMed Google Scholar
• Mak, P. A., Kast-Woelbern, H. R., Anisfeld, A. M. & Edwards, P. A. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J. Lipid Res. 43, 2037–2041 (2002).
  Article CAS PubMed Google Scholar
• Watanabe, M. et al. Bile acids lower triglyceride levels via a pathway involving, FXR, SHP, and SREBP-1c. J. Clin. Invest. 113, 1408–1418 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Matsukuma, K. E. et al. Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase. J. Lipid Res. 47, 2754–2761 (2006).
  Article CAS PubMed Google Scholar
• Pineda Torra, I. et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor-γ gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17, 259–272 (2003).
  Article PubMed CAS Google Scholar
• Zhang, Y., Castellani, L. W., Sinal, C. J., Gonzalez, F. J. & Edwards, P. A. Peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 18, 157–169 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Duran-Sandoval, D. et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J. Biol. Chem. 280, 29971–29979 (2005).
  Article CAS PubMed Google Scholar
• Zhang, Y. et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl Acad. Sci. USA 103, 1006–1011 (2006). This study shows that activation of FXR reduces blood glucose levels and improves insulin sensitivity in diabetic mice.
  Article CAS PubMed PubMed Central Google Scholar
• Ma, K., Saha, P. K., Chan, L. & Moore, D. D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 116, 1102–1109 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Ge, X. et al. Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis. J. Lipid Res. 52, 1561–1568 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Potthoff, M. J. et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab. 13, 729–738 (2011). This study describes a new mechanism by which mouse FGF15 and human FGF19 suppress gluconeogenesis. Given that FGF15 and FGF19 are FXR targets, this suggests a novel mechanism by which FXR may control carbohydrate metabolism.
  Article CAS PubMed PubMed Central Google Scholar
• Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621–1624 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ketterer, C. et al. Genetic variation within the NR1H2 gene encoding liver X receptor-β associates with insulin secretion in subjects at increased risk for type 2 diabetes. J. Mol. Med. (Berl.) 89, 75–81 (2011).
  Article CAS Google Scholar
• Dahlman, I. et al. Liver X receptor gene polymorphisms and adipose tissue expression levels in obesity. Pharmacogenet. Genomics 16, 881–889 (2006).
  Article CAS PubMed Google Scholar
• Solaas, K. et al. Suggestive evidence of associations between liver X receptor-β polymorphisms with type 2 diabetes mellitus and obesity in three cohort studies: HUNT2 (Norway), MONICA (France) and HELENA (Europe). BMC Med. Genet. 11, 144 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Auboeuf, D. et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46, 1319–1327 (1997).
  Article CAS PubMed Google Scholar
• Grefhorst, A. et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am. J. Physiol. Endocrinol. Metab. 289, E829–E838 (2005).
  Article CAS PubMed Google Scholar
• Commerford, S. R. et al. Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol. Endocrinol. 21, 3002–3012 (2007).
  Article CAS PubMed Google Scholar
• Fernandez-Veledo, S., Vila-Bedmar, R., Nieto-Vazquez, I. & Lorenzo, M. c-Jun N-terminal kinase 1/2 activation by tumour necrosis factor-α induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists. J. Clin. Endocrinol. Metab. 94, 3583–3593 (2009).
  Article CAS PubMed Google Scholar
• Shang, Q., Saumoy, M., Holst, J. J., Salen, G. & Xu, G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G419–G424 (2010).
  Article CAS PubMed Google Scholar
• Li, T. et al. Transgenic expression of cholesterol 7α-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 52, 678–690 (2010).
  Article CAS PubMed Google Scholar
• Bays, H. E., Goldberg, R. B., Truitt, K. E. & Jones, M. R. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch. Intern. Med. 168, 1975–1983 (2008).
  Article CAS PubMed Google Scholar
• Cipriani, S., Mencarelli, A., Palladino, G. & Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51, 771–784 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Cariou, B. et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281, 11039–11049 (2006).
  Article CAS PubMed Google Scholar
• Watanabe, M. et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem. 286, 26913–26920 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Prawitt, J. et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60, 1861–1871 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 99, 7604–7609 (2002). The first demonstration of the anti-atherosclerotic effects of LXR agonists.
  Article CAS PubMed PubMed Central Google Scholar
• Levin, N. et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25, 135–142 (2005). This study describes the importance of macrophages in the atheroprotective effects of LXR agonists.
  Article CAS PubMed Google Scholar
• Verschuren, L., de Vries-van der Weij, J., Zadelaar, S., Kleemann, R. & Kooistra, T. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. J. Lipid Res. 50, 301–311 (2009).
  Article CAS PubMed Google Scholar
• Terasaka, N. et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536, 6–11 (2003).
  Article CAS PubMed Google Scholar
• Schuster, G. U. et al. Accumulation of foam cells in liver X receptor-deficient mice. Circulation 106, 1147–1153 (2002).
  Article CAS PubMed Google Scholar
• Bradley, M. N. et al. Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE. J. Clin. Invest. 117, 2337–2346 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Tangirala, R. K. et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl Acad. Sci. USA 99, 11896–11901 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Teupser, D. et al. Effect of macrophage overexpression of murine liver X receptor-α (LXR-α) on atherosclerosis in LDL-receptor deficient mice. Arterioscler. Thromb. Vasc. Biol. 28, 2009–2015 (2008).
  Article CAS PubMed Google Scholar
• Bischoff, E. D. et al. Non-redundant roles for LXRα and LXRβ in atherosclerosis susceptibility in low density receptor knockout mice. J. Lipid Res. 51, 900–906 (2010).
  CAS PubMed PubMed Central Google Scholar
• Zhang, Y. et al. FXR deficiency causes reduced atherosclerosis in _Ldlr_−/− mice. Arterioscler. Thromb. Vasc. Biol. 26, 2316–2321 (2006).
  Article CAS PubMed Google Scholar
• Hanniman, E. A., Lambert, G., McCarthy, T. C. & Sinal, C. J. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46, 2595–2604 (2005).
  Article CAS PubMed Google Scholar
• Guo, G. L. et al. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta 1761, 1401–1409 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Flatt, B. et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J. Med. Chem. 52, 904–907 (2009).
  Article CAS PubMed Google Scholar
• Hartman, H. B. et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in _LDLR_−/− and _apoE_−/− mice. J. Lipid Res. 50, 1090–1100 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296, H272–H281 (2009).
  Article CAS PubMed Google Scholar